Dechra Veterinary Products
(A business unit of Dechra
Pharmaceuticals PLC)
Sansaw Business Park
Hadnall, Shrewsbury
Shropshire SY4 4AS
Tel: 01939 211200
Overdose: Local anaesthetics may have systemic adverse effects as a result of the raised plasma Presentation Contains: Active substances:
concentrations which occur when the rate of absorp- Lignocaine (lidocaine) hydrochloride 2.0% w/v tion exceeds the rate of breakdown. Toxicity causes Adrenaline* (epinephrine) acid tartrate 0.00198% excitation of the central nervous system, which may w/v *Including a 10% manufacturing overage be followed by systemic depression leading to coma.
Excipients: Sodium chloride, sodium metabisul- Convulsions may be controlled with diazepam.
phite, chlorocresol, water for injections.
Withdrawal period: Horse meat: zero days.
Sterile, aqueous solution for injection.
Incompatibilities: None known.
A local anaesthetic agent for regional nerve Pharmaceutical precautions
block, paravertebral nerve block and infiltration an- 25˚C. Protect from light. Discard unused material.
aesthesia, for use in dogs, cats and horses.
Do not use after the expiry date stated on the label.
Shelf life of the veterinary medicinal product as Dosage and administration
Shelf life after first opening the immediate packag- Cat infiltration
Disposal: Any unused veterinary medicinal product Dog infiltration
or waste materials derived from such veterinary Horse infiltration
medicinal products should be disposed of in accor- Legal category POM-VPS
Contraindications, warnings, etc
Packaging quantities
with a red rubber plug and an aluminium seal, Special precautions for use in animals: Do not containing a sterile, aqueous solution.
administer by intravenous injection.
Further information
Do not use for more than one induction of anaes- be supplied only on veterinary prescription. Keep out Special precautions to be taken by the person Date of last review: December 2012 administering the veterinary medicinal product toanimals: Following accidental self-injection or inges- Marketing authorisation holder (if different from
tion, seek medical advice taking the vial with you.
Following eye contamination or excessive skin con- Industrial Estate, Talke Pits, Stoke-on-Trent, Stafford- tact, irrigate/wash thoroughly with cold running wa- ter. Seek medical advice if irritation persists.
Marketing authorisation number Vm 10434/4028
Adverse reactions: None known.
Use during pregnancy and lactation: Use with GTIN (Global Trade Item No)
Requested by: lynne.easton@dechra.com
Approved datasheets found: 1
Creation date: 9/10/2013 14:26:6 (UK)
Approved for book but not on website: 0
Datasheets marked as draft (ignored): 0
Directory of participants
Dechra Veterinary Products
(A business unit of Dechra
Pharmaceuticals PLC)
Sansaw Business Park
Hadnall, Shrewsbury
Shropshire SY4 4AS
Tel: 01939 211200Fax: 01939 211201email: info.uk@dechra.comwww.dechra.com LIST OF PRODUCTS BY THERAPEUTIC INDICATION List of Products by Therapeutic Indication
Neurological preparations
Local anaesthetics
List of Products by Species
Please note that a species in brackets after a product name may not necessarily be a part of that product namebut is intended to make the index easier to use.
Horses and other equidae
Lignol 2.0% w/v Solution for Injection
List of Products by Active Ingredients
This index of non-proprietary names (active ingredients) is provided to enable users of the Compendium toidentify the brand names of relevant products when only the non-proprietary names are known.
It should be noted that although different products may contain the same active ingredient this does not implythat they are equivalent in regard to bioavailability or therapeutic activity.
Some products contain a number of ingredients and it has not been possible in every instance to identify suchproducts by a reference in this index to each ingredient.
Non-proprietary name in bold type. Proprietary name in ordinary type.
Lidocaine Hydrochloride (Lignocaine Hydrochloride)

Alphabetical Index of Products

Source: http://specific.eu/files/dechra/Downloads/Pharma/Datasheets/Lignol_2_0_w_v_Solution_for.pdf%2008-10-2013.pdf


HIGHLIGHTS OF PRESCRIBING INFORMATION ——— DOSAGE AND ADMINISTRATION ——— • The repaglinide component can cause hypoglycemia. Initiate These highlights do not include all the information needed • The dosage of PrandiMet® should be individualized. (2)PrandiMet® at the lowest available dose in patients naive to to use PrandiMet ® safely and effectively. See full • St


File No: TA4-01429 Toronto: December 8, 2004 IMMIGRATION AND REFUGEE BOARD JEREMY DEAN HINZMAN NGA NGUYEN LIAM HINZMAN CLAIMANTS PRESIDING MEMBER: B. Goodman J. House FOR THE CLAIMANTS REFUGEE PROTECTION OFFICER: MINISTER’S COUNSEL: CASE OFFICER: everyone. For those of you who are here for the first time,welcome. For those of you who are returning, welco

Copyright © 2014 Articles Finder